Clarity Pharmaceuticals achieves recruitment target for phase II SAR-Bombesin prostate cancer trial
Clinical-stage radiopharma company Clarity Pharmaceuticals (ASX:CU6) has imaged 50 patients with Cu-SAR-Bombesin…
Clarity Pharmaceuticals Ltd (ASX:CU6)
About Clarity Pharmaceuticals Ltd
Key Information
CU6 In the News
ASX Announcements
| Date | Announcement | File | Views |
|---|---|---|---|
| 15/04/2024 | Change in substantial holding | 825.9KB | 337 |
| 15/04/2024 | Cleaning Notice | 595.23KB | 228 |
| 15/04/2024 | Application for quotation of securities - CU6 | 22.64KB | 190 |
| 15/04/2024 | Ceasing to be a substantial holder - Taylor | 227.52KB | 331 |
| 15/04/2024 | Change in substantial holding - Cabbit Pty Ltd | 427.02KB | 305 |
| 08/04/2024 | Cleansing Notice | 229.67KB | 322 |
| 05/04/2024 | Application for quotation of securities - CU6 | 16.14KB | 271 |
| 04/04/2024 | Clarity enters into Clinical Supply Agreement | 209.49KB | 3.4K |